{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T06:19:43Z","timestamp":1783491583825,"version":"3.55.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      This study evaluated the prognostic value of intraprostatic maximum standardized uptake value (SUV\n                      <jats:sub>max<\/jats:sub>\n                      ) on primary-staging gallium-68 prostate-specific membrane antigen (\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA) PET\/computed tomography for predicting biochemical recurrence (BCR) and BCR-free survival after margin-negative radical prostatectomy, and explored an SUV\n                      <jats:sub>max<\/jats:sub>\n                      cutoff.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study included 78 men (2023\u20132024) who underwent preoperative\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA PET\/computed tomography, all reevaluated by an experienced nuclear medicine physician. BCR was defined as prostate-specific antigen at least 0.2\u2005ng\/ml on two consecutive tests. Follow up duration and time to recurrence were recorded. Mann\u2013Whitney U, \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      , receiver operating characteristic, Kaplan\u2013Meier, and Cox regression analyses were performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      BCR occurred in 21 of 78 patients (26.9%). Median follow up was 18 months, and median time to BCR was 12 months. Intraprostatic SUV\n                      <jats:sub>max<\/jats:sub>\n                      was significantly higher in patients with BCR (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.001). Receiver operating characteristic analysis showed an area under the curve of 0.798; the exploratory cutoff was 12.8, with 71.4% sensitivity and 84.2% specificity. Kaplan\u2013Meier analysis showed significantly worse BCR-free survival in patients with SUV\n                      <jats:sub>max<\/jats:sub>\n                      at least 12.8 (log-rank\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.001). In univariable Cox analysis, each 1-unit increase in SUV\n                      <jats:sub>max<\/jats:sub>\n                      was associated with higher BCR risk (hazard ratio\u2005=\u20051.11, 95% confidence interval 1.06\u20131.16,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.001), and this association remained significant in limited multivariable models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Intraprostatic SUV\n                      <jats:sub>max<\/jats:sub>\n                      appears to be an exploratory imaging biomarker associated with postoperative BCR and shorter BCR-free survival rather than a stand-alone prognostic determinant. Larger prospective multicenter studies are needed for validation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mnm.0000000000002149","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T07:07:23Z","timestamp":1775545643000},"page":"959-965","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of preoperative gallium-68 prostate-specific membrane antigen PET\/computed tomography in predicting biochemical recurrence after radical prostatectomy"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4839-9981","authenticated-orcid":false,"given":"H\u00fcseyin Mert","family":"Durak","sequence":"first","affiliation":[{"name":"Deparment of Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adem","family":"Sanci","sequence":"additional","affiliation":[{"name":"Deparment of Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Hep\u015fen","sequence":"additional","affiliation":[{"name":"Deparment of Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metin","family":"Yi\u011fman","sequence":"additional","affiliation":[{"name":"Deparment of Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alev","family":"\u00c7inar","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Ankara Etlik City Hospital, Ankara"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azmi Levent","family":"Sa\u011fnak","sequence":"additional","affiliation":[{"name":"Deparment of Urology, Siirt University, Siirt, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Nihat","family":"Karakoyunlu","sequence":"additional","affiliation":[{"name":"Deparment of Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"R1-20260708","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20260708","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.eururo.2013.03.005","article-title":"Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity.","volume":"64","author":"Nepple","year":"2013","journal-title":"Eur Urol"},{"key":"R3-20260708","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eururo.2015.11.010","article-title":"Surgery versus radiotherapy for clinicallylocalized prostate cancer: a systematic review and metaanalysis.","volume":"70","author":"Wallis","year":"2016","journal-title":"Eur Urol"},{"key":"R4-20260708","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.juro.2006.10.097","article-title":"Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.","volume":"177","author":"Cookson","year":"2007","journal-title":"J Urol"},{"key":"R5-20260708","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1111\/j.1464-410X.2011.10758.x","article-title":"Validation and comparison of the two Kattan nomograms in patients with prostate cancer treated with (125) iodine brachytherapy.","volume":"109","author":"Kattan","year":"2012","journal-title":"BJU Int"},{"key":"R6-20260708","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1002\/cncr.26169","article-title":"The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy.","volume":"117","author":"Cooperberg","year":"2011","journal-title":"Cancer"},{"key":"R7-20260708","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eururo.2013.08.036","article-title":"Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality.","volume":"65","author":"Stephenson","year":"2014","journal-title":"Eur Urol"},{"key":"R8-20260708","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/pros.22784","article-title":"Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer.","volume":"74","author":"Eder","year":"2014","journal-title":"Prostate"},{"key":"R9-20260708","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/1078-1439(95)00002-Y","article-title":"Expression of prostate-specific membrane antigen in normal, benign and malignant prostate tissues.","volume":"1","author":"Wright","year":"1995","journal-title":"Urol Oncol"},{"key":"R10-20260708","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2967\/jnumed.115.169243","article-title":"Correlation of intraprostatic tumor extent with 68Ga-PSMA distribution in patients with prostate cancer.","volume":"57","author":"Rahbar","year":"2016","journal-title":"J Nucl Med"},{"key":"R11-20260708","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2967\/jnumed.117.195172","article-title":"Immunohistochemical validation of PSMA-expression measured by Ga68-PSMA PET\/CT in primary prostate cancer.","volume":"59","author":"Woythal","year":"2017","journal-title":"J Nucl Med"},{"key":"R12-20260708","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00432-016-2262-9","article-title":"Management of prostate cancer patients with locally adverse pathologic features after radical prostatectomy: feasibility of active surveillance for cases with Gleason grade 3\u2009+\u20094 = 7.","volume":"143","author":"Shangguan","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"R13-20260708","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent.","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"R14-20260708","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-5347(05)67457-5","article-title":"Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.","volume":"164","author":"Amling","year":"2000","journal-title":"J Urol"},{"key":"R15-20260708","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0094-0143(05)70163-4","article-title":"Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.","volume":"28","author":"Han","year":"2001","journal-title":"Urol Clin North Am"},{"key":"R16-20260708","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00259-017-3631-6","article-title":"68Ga-PSMA-11 PET\/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.","volume":"44","author":"Uprimny","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R17-20260708","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/MNM.0000000000000942","article-title":"Can SUVmax values of Ga-68-PSMA PET\/CT scan predict the clinically significant prostate cancer?","volume":"40","author":"Demirci","year":"2019","journal-title":"Nucl Med Commun"},{"key":"R18-20260708","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00345-024-05012-2","article-title":"The role of PSMA PET\/CT in predicting downgrading in patients with Gleason score 4\u2009+\u20094 prostate cancer in prostate biopsy.","volume":"42","author":"Aykanat","year":"2024","journal-title":"World J Urol"},{"key":"R19-20260708","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00259-020-04944-2","article-title":"68Ga-PSMA PET\/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer.","volume":"48","author":"Roberts","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T06:01:13Z","timestamp":1783490473000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000002149","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"2026-01-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}